Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2020-01-23 | HOOK | Hookipa Pharma Inc. | Lilja Anders | SVP, Technical Development | S - Sale+OE | $12.59 | -11,643 | 0 | -100% | -$146,533 | |||||
| D | 2020-01-23 | FULC | Fulcrum Therapeutics, Inc. | Thomson Peter G. | VP Finance, Accounting | S - Sale+OE | $17.22 | -5,000 | 33,571 | -13% | -$86,102 | |||||
| D | 2020-01-23 | VCNX | Vaccinex, Inc. | Friedberg Albert | Dir, 10% | P - Purchase | $5.09 | +982,318 | 8,661,851 | +13% | +$4,999,999 | |||||
| D | 2020-01-23 | VCNX | Vaccinex, Inc. | Frieberg Jacob B. | Dir | P - Purchase | $5.09 | +39,292 | 39,292 | New | +$199,996 | |||||
| D | 2020-01-23 | VCNX | Vaccinex, Inc. | Zauderer Maurice | Pres, CEO, 10% | P - Purchase | $5.09 | +98,231 | 1,700,871 | +6% | +$499,996 | |||||
2020-01-23 | PTCT | Ptc Therapeutics, Inc. | Souza Marcio | COO | S - Sale | $53.25 | -154 | 5,074 | -3% | -$8,200 | ||||||
2020-01-23 | PTCT | Ptc Therapeutics, Inc. | Hill Emily Luisa | CFO | S - Sale | $53.25 | -330 | 6,891 | -5% | -$17,572 | ||||||
2020-01-23 | PTCT | Ptc Therapeutics, Inc. | Peltz Stuart Walter | CEO | S - Sale | $53.25 | -423 | 18,102 | -2% | -$22,523 | ||||||
| D | 2020-01-24 | BCEL | Atreca, Inc. | Greenberg Norman Michael | Chief Scientific Officer | S - Sale+OE | $18.47 | -5,000 | 0 | -100% | -$92,346 | |||||
2020-01-23 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | Chief Technical Ops Officer | S - Sale | $53.25 | -46 | 5,987 | -1% | -$2,449 | ||||||
2020-01-23 | ESPR | Esperion Therapeutics, Inc. | Biotech Target N V | 10% | P - Purchase | $52.12 | +20,000 | 3,747,964 | +1% | +$1,042,398 | ||||||
2020-01-24 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.58 | +50,000 | 222,329,181 | 0% | +$79,000 | ||||||
2020-01-22 | STML | Stemline Therapeutics Inc | Hoberman Kenneth | COO | S - Sale | $7.02 | -22,139 | 601,085 | -4% | -$155,416 | ||||||
| D | 2020-01-22 | BHVN | Biohaven Pharmaceutical Holding Co Ltd. | Aguiar Eric | Dir | S - Sale+OE | $56.48 | -2,021 | 1,250 | -62% | -$114,152 | |||||
| D | 2020-01-23 | IRWD | Ironwood Pharmaceuticals Inc | Currie Mark G | Dir | S - Sale+OE | $12.59 | -60,000 | 549,272 | -10% | -$755,400 | |||||
2020-01-22 | KRTX | Karuna Therapeutics, Inc. | Puretech Health LLC | 10% | S - Sale | $95.67 | -2,100,000 | 5,295,397 | -28% | -$200,907,000 | ||||||
| D | 2020-01-22 | VRTX | Vertex Pharmaceuticals Inc / Ma | Parini Michael | EVP, CL, AO | S - Sale+OE | $237.50 | -1 | 35,003 | 0% | -$238 | |||||
| D | 2020-01-22 | DCPH | Deciphera Pharmaceuticals, Inc. | Martin Daniel C. | Chief Commercial Officer | S - Sale+OE | $67.18 | -26,999 | 17,000 | -61% | -$1,813,709 | |||||
| AM | 2019-12-30 | ENDV | Endonovo Therapeutics, Inc. | Collier Alan Brian | CEO | P - Purchase | $2.00 | +200 | 25,719 | +1% | +$400 | |||||
| AM | 2019-12-10 | ENDV | Endonovo Therapeutics, Inc. | Collier Alan Brian | CEO | P - Purchase | $0.03 | +5,700 | 25,519 | +29% | +$163 | |||||
2020-01-23 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.63 | +50,000 | 222,279,181 | 0% | +$81,500 | ||||||
| M | 2019-12-30 | ENDV | Endonovo Therapeutics, Inc. | Collier Alan Brian | Ceo | P - Purchase | $2.00 | +200 | 25,418,897 | 0% | +$400 | |||||
2020-01-21 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres,COB,CEO,CFO, 10% | P - Purchase | $0.33 | +1,000 | 7,200,556 | 0% | +$330 | ||||||
| D | 2020-01-21 | CCXI | Chemocentryx, Inc. | Cappel Markus J. | Chief Bus. Officer, Treasurer | S - Sale+OE | $44.00 | -1,259 | 76,247 | -2% | -$55,392 | |||||
| D | 2020-01-22 | ALBO | Albireo Pharma, Inc. | Horn Patrick Taylor | Chief Medical Officer | S - Sale+OE | $24.29 | -443 | 4,557 | -9% | -$10,760 | |||||
| D | 2020-01-22 | ALBO | Albireo Pharma, Inc. | Duncan Jason | GC, GC | S - Sale+OE | $23.97 | -447 | 4,553 | -9% | -$10,715 | |||||
| D | 2020-01-21 | ARWR | Arrowhead Pharmaceuticals, Inc. | Myszkowski Kenneth Allen | CFO | S - Sale+OE | $49.44 | -40,313 | 384,223 | -9% | -$1,992,925 | |||||
2020-01-22 | APTX | Aptinyx Inc. | Sherman Rachel E. | Dir | P - Purchase | $4.79 | +2,174 | 2,174 | New | +$10,413 | ||||||
2020-01-21 | ADMS | Adamas Pharmaceuticals Inc | Prentiss Christopher B | CFO | S - Sale | $5.92 | -1,269 | 70,940 | -2% | -$7,512 | ||||||
| D | 2020-01-21 | ZTS | Zoetis Inc. | Chen Heidi C. | EVP | S - Sale+OE | $139.81 | -15,329 | 11,463 | -57% | -$2,143,115 | |||||
2020-01-21 | BDSI | Biodelivery Sciences International Inc | Plesha Scott M. | See Remarks | S - Sale | $5.77 | -15,000 | 192,336 | -7% | -$86,550 | ||||||
2020-01-21 | AMPH | Amphastar Pharmaceuticals, Inc. | Peters William J | CFO, SVP, Treasurer | S - Sale | $20.07 | -3,990 | 78,975 | -5% | -$80,071 | ||||||
| M | 2020-01-21 | GBT | Global Blood Therapeutics, Inc. | Love Ted W | See Remarks | S - Sale | $81.96 | -80,000 | 1,066,984 | -7% | -$6,557,148 | |||||
2020-01-21 | EQ | Equillium, Inc. | Keyes Jason A | CFO | S - Sale | $4.41 | -5,000 | 135,520 | -4% | -$22,043 | ||||||
| D | 2020-01-21 | BGNE | Beigene, Ltd. | Huang Jane | CMO, Hematology | S - Sale+OE | $170.69 | -1,500 | 291,667 | -1% | -$256,042 | |||||
| D | 2020-01-21 | COLL | Collegium Pharmaceutical, Inc | Heffernan Michael Thomas | Dir | S - Sale+OE | $21.93 | -295,287 | 106,012 | -74% | -$6,476,863 | |||||
2020-01-21 | TYME | Tyme Technologies, Inc. | Demurjian Michael | 10% | S - Sale | $1.90 | -20,000 | 25,030,521 | 0% | -$37,900 | ||||||
| D | 2020-01-17 | BCEL | Atreca, Inc. | Cavet Guy | Chief Technical Officer | S - Sale+OE | $14.90 | -6,919 | 102,758 | -6% | -$103,065 | |||||
| D | 2020-01-17 | BCEL | Atreca, Inc. | Greenberg Norman Michael | Chief Scientific Officer | S - Sale+OE | $14.90 | -10,000 | 0 | -100% | -$148,992 | |||||
| D | 2020-01-21 | CWBR | Cohbar, Inc. | Biunno Jeffrey Francis | CFO, Treasurer, Secretary | S - Sale+OE | $2.19 | -5,000 | 11,000 | -31% | -$10,950 | |||||
| M | 2020-01-16 | AKRO | Akero Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $20.87 | -59,532 | 3,092,698 | -2% | -$1,242,403 | |||||
| D | 2020-01-17 | DRNA | Dicerna Pharmaceuticals Inc | Green John B | CFO | S - Sale+OE | $21.27 | -47,969 | 19,421 | -71% | -$1,020,164 | |||||
2020-01-17 | RARX | Ra Pharmaceuticals, Inc. | Ricardo Alonso | See Remarks | S - Sale | $47.02 | -2,285 | 2,288 | -50% | -$107,441 | ||||||
| D | 2020-01-16 | AIMT | Aimmune Therapeutics, Inc. | Sheehy Douglas T. | See Remarks | S - Sale+OE | $37.00 | -400 | 45,668 | -1% | -$14,800 | |||||
2020-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Morningside Venture Investments Ltd | 10% | P - Purchase | $37.00 | +540,540 | 12,556,342 | +4% | +$19,999,980 | ||||||
| D | 2020-01-16 | IRWD | Ironwood Pharmaceuticals Inc | Currie Mark G | Dir | S - Sale+OE | $12.80 | -8,888 | 549,272 | -2% | -$113,766 | |||||
2020-01-17 | GALT | Galectin Therapeutics Inc | 10X Fund, L.P. | 10% | S - Sale | $2.97 | -10,000 | 6,375,790 | 0% | -$29,700 | ||||||
| DM | 2020-01-16 | HOOK | Hookipa Pharma Inc. | Orlinger Klaus | SVP, Research | S - Sale+OE | $11.93 | -8,500 | 0 | -100% | -$101,373 | |||||
2020-01-16 | ONCS | Oncosec Medical Inc | Bonstein Sara | CFO, COO | S - Sale | $2.08 | -1,351 | 41,389 | -3% | -$2,810 | ||||||
| D | 2020-01-16 | VRTX | Vertex Pharmaceuticals Inc / Ma | Sachdev Amit | EVP, Chief Patient Officer | S - Sale+OE | $235.00 | -5,000 | 53,262 | -9% | -$1,175,000 | |||||
2020-01-16 | EVFM | Evofem Biosciences, Inc. | Barrans Russell | Chief Commercial Officer | S - Sale | $6.50 | -1,578 | 196,577 | -1% | -$10,257 | ||||||
2020-01-17 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.56 | +22,262 | 222,229,181 | 0% | +$34,729 | ||||||
| DM | 2020-01-16 | CCXI | Chemocentryx, Inc. | Schall Thomas J. | Pres, CEO | S - Sale+OE | $41.47 | -136,052 | 2,268,557 | -6% | -$5,641,441 | |||||
| DM | 2020-01-16 | CCXI | Chemocentryx, Inc. | Kanaya Susan M | EVP, CFO, Sec. | S - Sale+OE | $41.00 | -62,998 | 185,497 | -25% | -$2,582,831 | |||||
| D | 2020-01-16 | CCXI | Chemocentryx, Inc. | Cappel Markus J. | Chief Bus. Officer, Treasurer | S - Sale+OE | $40.07 | -50,000 | 76,247 | -40% | -$2,003,480 | |||||
| D | 2020-01-16 | CCXI | Chemocentryx, Inc. | Kwan Pui San | Principal Acctg Officer | S - Sale+OE | $39.91 | -89,179 | 19,434 | -82% | -$3,559,216 | |||||
| M | 2020-01-16 | SPPI | Spectrum Pharmaceuticals Inc | Gustafson Kurt A | EVP, CFO | S - Sale | $3.35 | -4,143 | 240,001 | -2% | -$13,890 | |||||
| M | 2020-01-16 | SPPI | Spectrum Pharmaceuticals Inc | Turgeon Joseph W. | CEO, Pres | S - Sale | $3.35 | -5,697 | 425,280 | -1% | -$19,110 | |||||
| D | 2020-01-15 | PCRX | Pacira Biosciences, Inc. | Stack David M | CEO, COB | S - Sale+OE | $42.68 | -25,000 | 182,282 | -12% | -$1,066,968 | |||||
| M | 2020-01-16 | SPPI | Spectrum Pharmaceuticals Inc | Riga Thomas J | EVP, COO, CCO | S - Sale | $3.33 | -16,381 | 249,776 | -6% | -$54,620 | |||||
2020-01-15 | FOLD | Amicus Therapeutics, Inc. | Rosenberg Ellen | GC | S - Sale | $10.35 | -22,100 | 200,350 | -10% | -$228,642 | ||||||
2020-01-15 | FOLD | Amicus Therapeutics, Inc. | Barth Jay | Chief Medical Officer | S - Sale | $10.35 | -20,720 | 156,493 | -12% | -$214,359 | ||||||
2020-01-15 | FOLD | Amicus Therapeutics, Inc. | Campbell Bradley L | COO | S - Sale | $10.35 | -5,064 | 370,520 | -1% | -$52,388 | ||||||
| D | 2020-01-15 | FOLD | Amicus Therapeutics, Inc. | Crowley John F | COB, CEO | S - Sale+OE | $10.35 | -100,000 | 1,023,234 | -9% | -$1,034,790 | |||||
2020-01-15 | TPTX | Turning Point Therapeutics, Inc. | Cui Jingrong Jean | Chief Scientific Officer | S - Sale | $53.12 | -11,500 | 2,170,517 | -1% | -$610,853 | ||||||
2020-01-15 | GWPH | Gw Pharmaceuticals Plc | Guy Geoffrey W Dr | Exec COB | S - Sale | $9.44 | -900,000 | 6,821,521 | -12% | -$8,493,000 | ||||||
2020-01-16 | EBS | Emergent Biosolutions Inc. | Harsanyi Zsolt | Dir | S - Sale | $55.00 | -3,435 | 36,273 | -9% | -$188,925 | ||||||
| D | 2020-01-15 | APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | CEO | S - Sale+OE | $42.11 | -35,638 | 1,236,204 | -3% | -$1,500,787 | |||||
| DM | 2020-01-15 | DCPH | Deciphera Pharmaceuticals, Inc. | Morl Christopher John | Chief Business Officer | S - Sale+OE | $65.27 | -15,034 | 0 | -100% | -$981,205 | |||||
| D | 2020-01-15 | APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Dir | S - Sale+OE | $41.47 | -2,500 | 670,474 | 0% | -$103,675 | |||||
| D | 2020-01-16 | BDSI | Biodelivery Sciences International Inc | Coelho Mary Theresa | See Remarks | S - Sale+OE | $5.98 | -42,018 | 12,018 | -78% | -$251,268 | |||||
| D | 2020-01-15 | QURE | Uniqure N.V. | Kuta Alexander Edward III | EVP, Operations | S - Sale+OE | $68.97 | -4,000 | 41,578 | -9% | -$275,880 | |||||
2020-01-15 | FTSV | Forty Seven, Inc. | Majeti Ravindra | Dir | S - Sale | $36.35 | -25,000 | 1,286,400 | -2% | -$908,698 | ||||||
| D | 2020-01-14 | BMRN | Biomarin Pharmaceutical Inc | Bienaime Jean Jacques | CEO | S - Sale+OE | $87.95 | -8,000 | 507,791 | -2% | -$703,600 | |||||
| D | 2020-01-14 | BBIO | Bridgebio Pharma, Inc. | Homcy Charles J | COB of Pharmaceuticals | S - Sale+OE | $35.00 | -10,000 | 1,362,291 | -1% | -$350,000 | |||||
| M | 2020-01-14 | EIDX | Eidos Therapeutics, Inc. | Fox Jonathan C | See Remarks | S - Sale | $55.01 | -10,000 | 433,107 | -2% | -$550,072 | |||||
2020-01-15 | TCDA | Tricida, Inc. | Klaerner Gerrit | Pres, CEO | S - Sale | $35.26 | -4,000 | 620,644 | -1% | -$141,040 | ||||||
| D | 2020-01-15 | RARX | Ra Pharmaceuticals, Inc. | Farzaneh-Far Ramin | Chief Medical Officer | S - Sale+OE | $46.95 | -10,595 | 7,132 | -60% | -$497,441 | |||||
2020-01-15 | MYOV | Myovant Sciences Ltd. | Sablich Kim | Chief Commercial Officer | S - Sale | $14.04 | -4,840 | 59,690 | -8% | -$67,954 | ||||||
2020-01-15 | ZTS | Zoetis Inc. | Trawicki Roman | EVP | S - Sale | $137.41 | -2,199 | 0 | -100% | -$302,165 | ||||||
2020-01-15 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $12.96 | -4,950 | 228,273 | -2% | -$64,159 | ||||||
2020-01-14 | APTX | Aptinyx Inc. | Koppel Adam | Dir, 10% | P - Purchase | $3.00 | +3,333,333 | 5,558,425 | +150% | +$9,999,999 | ||||||
2020-01-14 | COLL | Collegium Pharmaceutical, Inc | Dreyer Scott | EVP, Chief Commercial Officer | S - Sale | $23.87 | -1,321 | 35,716 | -4% | -$31,532 | ||||||
| D | 2020-01-14 | HOOK | Hookipa Pharma Inc. | Orlinger Klaus | SVP, Research | S - Sale+OE | $11.30 | -8,500 | 0 | -100% | -$96,053 | |||||
| DM | 2020-01-14 | CWBR | Cohbar, Inc. | Cundy Kenneth C | Chief Scientific Officer | S - Sale+OE | $1.91 | -17,981 | 10,000 | -64% | -$34,330 | |||||
| D | 2020-01-14 | CWBR | Cohbar, Inc. | Biunno Jeffrey Francis | CFO, Treasurer, Secretary | S - Sale+OE | $1.96 | -5,000 | 11,000 | -31% | -$9,800 | |||||
| M | 2020-01-10 | AKRO | Akero Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $20.04 | -50,837 | 3,152,230 | -2% | -$1,018,571 | |||||
| DM | 2020-01-13 | CCXI | Chemocentryx, Inc. | Cappel Markus J. | Chief Bus. Officer, Treasurer | S - Sale+OE | $37.27 | -116,456 | 76,247 | -60% | -$4,340,448 | |||||
2020-01-13 | CCXI | Chemocentryx, Inc. | Tyree James L | Dir | S - Sale | $37.06 | -30,000 | 5,345 | -85% | -$1,111,686 | ||||||
| D | 2020-01-13 | MRK | Merck & Co., Inc. | Gerberding Julie L. | EVP Strat Comm, GI Pub Policy | S - Sale+OE | $89.34 | -102,073 | 37,038 | -73% | -$9,118,865 | |||||
2020-01-13 | OSMT | Osmotica Pharmaceuticals Plc | Harsaul Foundation | 10% | P - Purchase | $5.00 | +1,250,000 | 22,485,297 | +6% | +$6,250,000 | ||||||
2020-01-13 | OSMT | Osmotica Pharmaceuticals Plc | Altchem Ltd | 10% | P - Purchase | $5.00 | +1,250,000 | 23,667,540 | +6% | +$6,250,000 | ||||||
2020-01-13 | EVFM | Evofem Biosciences, Inc. | File Justin J. | CFO | S - Sale | $6.00 | -1,648 | 177,251 | -1% | -$9,888 | ||||||
2020-01-13 | EVFM | Evofem Biosciences, Inc. | Pelletier Saundra L | CEO | S - Sale | $6.00 | -3,295 | 362,289 | -1% | -$19,770 | ||||||
2020-01-13 | YMAB | Y-Mabs Therapeutics, Inc. | Gad Thomas | Pres, COB | S - Sale | $30.90 | -4,000 | 1,886,356 | 0% | -$123,612 | ||||||
2020-01-13 | OSMT | Osmotica Pharmaceuticals Plc | Venkataraman Sriram | Dir, 10% | P - Purchase | $5.00 | +1,250,000 | 21,700,785 | +6% | +$6,250,000 | ||||||
2020-01-13 | OSMT | Osmotica Pharmaceuticals Plc | Burgstahler David F | Dir, 10% | P - Purchase | $5.00 | +1,250,000 | 21,700,785 | +6% | +$6,250,000 | ||||||
2020-01-13 | OSMT | Osmotica Pharmaceuticals Plc | Avista Capital Partners III Gp, L.P. | 10% | P - Purchase | $5.00 | +1,250,000 | 21,700,785 | +6% | +$6,250,000 | ||||||
2020-01-13 | JAZZ | Jazz Pharmaceuticals Plc | Miller Michael Patrick | EVP, US Commercial | S - Sale | $146.78 | -1,500 | 28,071 | -5% | -$220,170 | ||||||
| D | 2020-01-13 | VRTX | Vertex Pharmaceuticals Inc / Ma | Silva Paul M | SVP, Controller | S - Sale+OE | $229.38 | -860 | 17,928 | -5% | -$197,267 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |